NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free MNPR Stock Alerts $0.72 -0.03 (-4.51%) (As of 01:40 PM ET) Add Compare Share Share Today's Range$0.72▼$0.7850-Day Range$0.59▼$1.0652-Week Range$0.27▼$1.75Volume17,081 shsAverage Volume3.81 million shsMarket Capitalization$12.50 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Monopar Therapeutics alerts: Email Address Monopar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside173.6% Upside$2.00 Price TargetShort InterestHealthy2.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.67) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector454th out of 905 stocksPharmaceutical Preparations Industry206th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingMonopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMonopar Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Monopar Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.01% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 12.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNPR. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for Monopar Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat Follows4 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Monopar Therapeutics are expected to grow in the coming year, from ($0.67) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monopar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupTrump Asset Seizure Threat Alert: Could Your Savings Be Next?Trump Asset Seizures Threat A Warning For 401K Owners?Request Your FREE WEALTH PROTECTION GUIDE About Monopar Therapeutics Stock (NASDAQ:MNPR)Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Read More MNPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNPR Stock News HeadlinesMay 9, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | markets.businessinsider.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 9, 2024 | globenewswire.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 4, 2024 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Stock Price Up 10.2%May 1, 2024 | investing.comMonopar Therapeutics Inc (MNPR)April 18, 2024 | globenewswire.comMonopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingApril 16, 2024 | msn.comMonopar files patent protecting its MNPR-101 radiopharma optimization findingsMay 9, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 16, 2024 | finance.yahoo.comMonopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsApril 11, 2024 | markets.businessinsider.comBuy Rating on Monopar Therapeutics: Promising Trials and Financial Stability Highlight Growth PotentialApril 10, 2024 | globenewswire.comMonopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsMarch 28, 2024 | finance.yahoo.comMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 28, 2024 | globenewswire.comMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 6, 2024 | marketwatch.comMonpar Therapeutics Shares Rise 12% After Positive Preclinical Data for MNPR-101March 5, 2024 | markets.businessinsider.comMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramMarch 5, 2024 | globenewswire.comMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramFebruary 27, 2024 | globenewswire.comMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialFebruary 24, 2024 | cnn.comMonopar Therapeutics IncFebruary 23, 2024 | markets.businessinsider.comDow Surges Over 150 Points; AerCap Posts Upbeat EarningsFebruary 22, 2024 | msn.comWhat's Going On With Cancer-Focused Monopar Therapeutics Stock Today?February 22, 2024 | msn.comMonopar stock jumps 60% amid preclinical data for MNPR-101February 22, 2024 | finance.yahoo.comMonopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersFebruary 20, 2024 | benzinga.comCrude Oil Moves Lower; Summit Therapeutics Shares PlummetFebruary 20, 2024 | marketwatch.comMonopar Therapeutics Shares Surge on Australia Antibody-Trial ClearanceFebruary 20, 2024 | msn.comWhy Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?February 20, 2024 | finance.yahoo.comMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersSee More Headlines Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/09/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MNPR CUSIPN/A CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees9Year Founded2014Price Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+166.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.79% Return on Assets-88.05% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.97Miscellaneous Outstanding Shares17,450,000Free Float10,194,000Market Cap$13.09 million OptionableNot Optionable Beta1.17 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Chandler D. Robinson M.B.A. (Age 40)M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director Comp: $710.5kMs. Kim R. Tsuchimoto CPA (Age 61)CFO, Secretary, Treasurer & Director Comp: $354kMr. Andrew J. Cittadine M.B.A. (Age 51)Chief Operating Officer Comp: $416.7kDr. Patrice P. Rioux M.D. (Age 73)Ph.D., Acting Chief Medical Officer Key CompetitorsKiora PharmaceuticalsNASDAQ:KPRXRedHill BiopharmaNASDAQ:RDHLAvalo TherapeuticsNASDAQ:AVTXPieris PharmaceuticalsNASDAQ:PIRSPurple BiotechNASDAQ:PPBTView All Competitors MNPR Stock Analysis - Frequently Asked Questions Should I buy or sell Monopar Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNPR shares. View MNPR analyst ratings or view top-rated stocks. What is Monopar Therapeutics' stock price target for 2024? 1 equities research analysts have issued 12-month price objectives for Monopar Therapeutics' stock. Their MNPR share price targets range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price. View analysts price targets for MNPR or view top-rated stocks among Wall Street analysts. How have MNPR shares performed in 2024? Monopar Therapeutics' stock was trading at $0.3402 at the beginning of 2024. Since then, MNPR stock has increased by 114.9% and is now trading at $0.7311. View the best growth stocks for 2024 here. Are investors shorting Monopar Therapeutics? Monopar Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 170,500 shares, a decline of 25.7% from the March 15th total of 229,600 shares. Based on an average trading volume of 5,230,000 shares, the short-interest ratio is currently 0.0 days. Currently, 2.3% of the shares of the company are sold short. View Monopar Therapeutics' Short Interest. When is Monopar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MNPR earnings forecast. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) released its earnings results on Thursday, March, 28th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST). When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Monopar Therapeutics have any subsidiaries? The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.Read More This page (NASDAQ:MNPR) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
